The import of blood-grouping reagents in the UK is forecasted to decline steadily from 2024 to 2028, with values decreasing from 8.2183 million USD to 6.8594 million USD. This marks a consistent decrease over the five-year period, highlighting a trend towards reduced expenditure on such imports. The year-on-year percentage changes illustrate this downward trajectory with each subsequent year. Considering the compound annual growth rate (CAGR), the forecast indicates an average annual decline in import value over this period.
Future trends to watch for include potential shifts in domestic production capabilities or changes in healthcare policies that could impact import demand. Technological advancements in blood testing may also influence the market dynamics by altering consumption patterns.
